{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T09:25:29Z","timestamp":1794734729625,"version":"4.9.1"},"reference-count":216,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Cardiovascular (CV) disease, chronic kidney disease, obesity, and diabetes mellitus have reached epidemic proportions over the past few decades. Accumulating evidence highlights the strong interconnection between these conditions, leading to the definition of a broader disease entity known as cardio-renal-metabolic (CRM) syndrome. This newly recognized clinical entity presents important challenges in identifying the optimal treatment strategy within a holistic, patient-centered framework. In line with this, sodium glucose cotransporter 2 inhibitors (SGLT2is), owing to their multifaceted pharmacological effects, have been suggested as possible treatment options in the management of CRM. SGLT2is exert their antihyperglycemic effects by impeding the renal reabsorption of sodium and glucose, causing glycosuria and natriuresis. Research has confirmed that their unique beneficial effects extend beyond glycemic control, reducing CV death and hospitalizations in patients with heart failure, and the incidence of kidney failure in dedicated kidney outcome studies\u2014regardless of diabetes status. Furthermore, these agents contribute to weight loss and blood pressure reduction. Their benefits appear to stem from a combination of factors, which include reduced oxidative stress, lower levels of inflammation, regulated neurohormonal activation, improved endothelial function, and enhanced metabolic efficiency. This review aims to provide a comprehensive analysis of the pathophysiological mechanisms underlying the effects of SGLT2is in CRM syndrome, synthesize evidence from landmark clinical trials, evaluate current experimental and diagnostic approaches, and provide the emerging role of SGLT2is in the treatment of this new clinical entity.<\/jats:p>","DOI":"10.3390\/medicina61111903","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:47:36Z","timestamp":1761266856000},"page":"1903","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era"],"prefix":"10.3390","volume":"61","author":[{"given":"Konstantinos","family":"Grigoriou","sequence":"first","affiliation":[{"name":"Department of Pharmacology, University of Athens, 75 Mikras Asias Avenue, Goudi, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3561-5713","authenticated-orcid":false,"given":"Paschalis","family":"Karakasis","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3057-5297","authenticated-orcid":false,"given":"Athina","family":"Nasoufidou","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1657-4696","authenticated-orcid":false,"given":"Panagiotis","family":"Stachteas","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7870-0996","authenticated-orcid":false,"given":"Aleksandra","family":"Klisic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Montenegro, 81000 Podgorica, Montenegro"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8328-5942","authenticated-orcid":false,"given":"Efstratios","family":"Karagiannidis","sequence":"additional","affiliation":[{"name":"Emergency Department, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0019-0134","authenticated-orcid":false,"given":"Barbara","family":"Fyntanidou","sequence":"additional","affiliation":[{"name":"Emergency Department, AHEPA University General Hospital, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2763-1326","authenticated-orcid":false,"given":"Djordje S.","family":"Popovic","sequence":"additional","affiliation":[{"name":"Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre of Vojvodina, Medical Faculty, University of Novi Sad, 21000 Novi Sad, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6899-684X","authenticated-orcid":false,"given":"Dimitrios","family":"Patoulias","sequence":"additional","affiliation":[{"name":"Second Propedeutic Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6604-5581","authenticated-orcid":false,"given":"Antonios P.","family":"Antoniadis","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7158-4950","authenticated-orcid":false,"given":"Nikolaos","family":"Fragakis","sequence":"additional","affiliation":[{"name":"Second Department of Cardiology, Hippokration General Hospital, Aristotle University of Thessaloniki, Konstantinoupoleos 49, 54642 Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"key":"ref_1","unstructured":"GBD 2021 (2025). Adult BMI Collaborators. Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: A forecasting study for the Global Burden of Disease Study 2021. Lancet, 405, 813\u2013838."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.7861\/clinmed.2023-0168","article-title":"Causes of Obesity: A Review","volume":"23","author":"Masood","year":"2023","journal-title":"Clin. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Lin, X., Xu, Y., Pan, X., Xu, J., Ding, Y., Sun, X., Song, X., Ren, Y., and Shan, P.F. (2020). Global, Regional, and National Burden and Trend of Diabetes in 195 Countries and Territories: An Analysis from 1990 to 2025. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-71908-9"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Kolb, H., and Martin, S. (2017). Environmental\/Lifestyle Factors in the Pathogenesis and Prevention of Type 2 Diabetes. BMC Med., 15.","DOI":"10.1186\/s12916-017-0901-x"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.jacc.2019.10.009","article-title":"The Global Burden of Cardiovascular Diseases and Risk Factors: 2020 and Beyond","volume":"74","author":"Mensah","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","article-title":"Chronic Kidney Disease and the Global Public Health Agenda: An International Consensus","volume":"20","author":"Francis","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1001\/jamacardio.2023.3241","article-title":"Prevalence and Overlap of Cardiac, Renal, and Metabolic Conditions in US Adults, 1999\u20132020","volume":"8","author":"Ostrominski","year":"2023","journal-title":"JAMA Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Mutruc, V., Bologa, C., \u0218orodoc, V., Ceasovschih, A., Mor\u0103ra\u0219u, B.C., \u0218orodoc, L., Catar, O.E., and Lionte, C. (2025). Cardiovascular\u2013Kidney\u2013Metabolic Syndrome: A New Paradigm in Clinical Medicine or Going Back to Basics?. J. Clin. Med., 14.","DOI":"10.3390\/jcm14082833"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: A presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.jacc.2024.03.368","article-title":"Prevalence of the Cardiovascular-Kidney-Metabolic Syndrome in the United States","volume":"83","author":"Minhas","year":"2024","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Akiyama, H., Nishimura, A., Morita, N., and Yajima, T. (2023). Evolution of Sodium-Glucose Co-Transporter 2 Inhibitors from a Glucose-Lowering Drug to a Pivotal Therapeutic Agent for Cardio-Renal-Metabolic Syndrome. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1111984"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gajjar, A., Raju, A.K., Gajjar, A., Menon, M., Shah, S.A.Y., Dani, S., and Weinberg, A. (2025). SGLT2 Inhibitors and GLP-1 Receptor Agonists in Cardiovascular\u2013Kidney\u2013Metabolic Syndrome. Biomedicines, 13.","DOI":"10.3390\/biomedicines13081924"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Wang, Y., Wang, Y., He, X., and Li, X. (2025). Sodium-Glucose Transporter 2 Inhibitors and Cardiovascular-Kidney-Metabolic Syndrome: A Narrative Review. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1554637"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s10741-023-10324-3","article-title":"Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Mildly Reduced or Preserved Ejection Fraction: An Overview of 36 Systematic Reviews","volume":"28","author":"Karakasis","year":"2023","journal-title":"Heart Fail. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2304667","DOI":"10.1080\/07853890.2024.2304667","article-title":"The Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on Markers of Subclinical Atherosclerosis","volume":"55","author":"Stachteas","year":"2023","journal-title":"Ann. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s44324-025-00068-z","article-title":"SGLT2 Inhibitors Across Various Patient Populations in the Era of Precision Medicine: The Multidisciplinary Team Approach","volume":"3","author":"McLean","year":"2025","journal-title":"npj Metab. Health Dis."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Theodorakis, N., and Nikolaou, M. (2025). From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework. Biomolecules, 15.","DOI":"10.3390\/biom15020213"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"102344","DOI":"10.1016\/j.cpcardiol.2023.102344","article-title":"Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A State-of-the-Art Review","volume":"49","author":"Sebastian","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A Synopsis of the Evidence for the Science and Clinical Management of Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Scientific Statement From the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/endocrines5020011","article-title":"Mechanisms of Insulin Resistance in Patients with Obesity","volume":"5","author":"Arneth","year":"2024","journal-title":"Endocrines"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.3390\/nu5041218","article-title":"Dyslipidemia in Obesity: Mechanisms and Potential Targets","volume":"5","author":"Klop","year":"2013","journal-title":"Nutrients"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3000605231164548","DOI":"10.1177\/03000605231164548","article-title":"Insulin Resistance and Cardiovascular Disease","volume":"51","author":"Kosmas","year":"2023","journal-title":"J. Int. Med. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/ki.2015.305","article-title":"Molecular Mechanisms of Insulin Resistance in Chronic Kidney Disease","volume":"88","author":"Thomas","year":"2015","journal-title":"Kidney Int."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Pinto, R.S., Minanni, C.A., de Ara\u00fajo Lira, A.L., and Passarelli, M. (2022). Advanced Glycation End Products: A Sweet Flavor That Embitters Cardiovascular Disease. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052404"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Jha, R., Lopez-Trevino, S., Kankanamalage, H.R., and Jha, J.C. (2024). Diabetes and Renal Complications: An Overview on Pathophysiology, Biomarkers and Therapeutic Interventions. Biomedicines, 12.","DOI":"10.3390\/biomedicines12051098"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1161\/HYPERTENSIONAHA.121.17981","article-title":"Hypertension in Diabetes: An Update of Basic Mechanisms and Clinical Disease","volume":"78","author":"Jia","year":"2021","journal-title":"Hypertension"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/01.CIR.0000033824.02722.F7","article-title":"Aortic Pulse-Wave Velocity and Its Relationship to Mortality in Diabetes and Glucose Intolerance: An Integrated Index of Vascular Function?","volume":"106","author":"Cruickshank","year":"2002","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Costantino, V.V., Gil Lorenzo, A.F., Bocanegra, V., and Vall\u00e9s, P.G. (2021). Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70. Cells, 10.","DOI":"10.3390\/cells10113146"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1751-7176.2011.00434.x","article-title":"Comorbidities of Diabetes and Hypertension: Mechanisms and Approach to Target Organ Protection","volume":"13","author":"Long","year":"2011","journal-title":"J. Clin. Hypertens."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11906-015-0544-2","article-title":"Cardiovascular and Renal Effects of Weight Reduction in Obesity and the Metabolic Syndrome","volume":"17","author":"Cohen","year":"2015","journal-title":"Curr. Hypertens. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/CIRCULATIONAHA.106.171016","article-title":"Obesity and Cardiovascular Disease: Pathophysiology, Evaluation, and Effect of Weight Loss: An Update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism","volume":"113","author":"Poirier","year":"2006","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.pcad.2018.07.012","article-title":"Obesity and Cardiac Remodeling in Adults: Mechanisms and Clinical Implications","volume":"61","author":"Alpert","year":"2018","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Kreiner, F.F., Schytz, P.A., Heerspink, H.J.L., von Scholten, B.J., and Idorn, T. (2023). Obesity-Related Kidney Disease: Current Understanding and Future Perspectives. Biomedicines, 11.","DOI":"10.3390\/biomedicines11092498"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41581-025-00950-5","article-title":"From Fat to Filter: The Effect of Adipose Tissue-Derived Signals on Kidney Function","volume":"21","author":"Ahmed","year":"2025","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrneph.2013.250","article-title":"Cardiorenal Syndrome\u2014Current Understanding and Future Perspectives","volume":"10","author":"Braam","year":"2014","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Szlagor, M., Dybiec, J., M\u0142ynarska, E., Rysz, J., and Franczyk, B. (2023). Chronic Kidney Disease as a Comorbidity in Heart Failure. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032988"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Giglio, R.V., Patti, A.M., Rizvi, A.A., Stoian, A.P., Ciaccio, M., Papanas, N., Janez, A., Sonmez, A., Banach, M., and Sahebkar, A. (2023). Advances in the Pharmacological Management of Diabetic Nephropathy: A 2022 International Update. Biomedicines, 11.","DOI":"10.3390\/biomedicines11020291"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41581-024-00836-y","article-title":"Applications of SGLT2 Inhibitors Beyond Glycaemic Control","volume":"20","author":"Lam","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The Effect of Dapagliflozin Treatment on Epicardial Adipose Tissue Volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Tang, J., Ye, L., Yan, Q., Zhang, X., and Wang, L. (2022). Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.800490"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCULATIONAHA.123.064346","article-title":"Critical Analysis of the Effects of SGLT2 Inhibitors on Renal Tubular Sodium, Water and Chloride Homeostasis and Their Role in Influencing Heart Failure Outcomes","volume":"148","author":"Packer","year":"2023","journal-title":"Circulation"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3390\/kidneydial3010005","article-title":"Renal Mechanisms of Diuretic Resistance in Congestive Heart Failure","volume":"3","author":"Lameire","year":"2023","journal-title":"Kidney Dial."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Stachteas, P., Nasoufidou, A., Patoulias, D., Karakasis, P., Karagiannidis, E., Mourtzos, M.-A., Samaras, A., Apostolidou, X., and Fragakis, N. (2024). The Role of Sodium-Glucose Co-Transporter-2 Inhibitors on Diuretic Resistance in Heart Failure. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25063122"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/ehjcvp\/pvab056","article-title":"Cardio-Renal Benefits of Sodium\u2013Glucose Co-Transporter 2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Mechanisms and Clinical Evidence","volume":"8","author":"Correa","year":"2022","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","article-title":"Sodium-Glucose Cotransport Inhibition with Dapagliflozin in Type 2 Diabetes","volume":"32","author":"List","year":"2009","journal-title":"Diabetes Care"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin: A Glucose-Regulating Drug with Diuretic Properties in Subjects with Type 2 Diabetes","volume":"15","author":"Wie","year":"2013","journal-title":"Diabetes Obes. Metab."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/ki.2014.246","article-title":"Sodium Glucose Cotransport-2 Inhibition and Intrarenal RAS Activity in People with Type 1 Diabetes","volume":"86","author":"Cherney","year":"2014","journal-title":"Kidney Int."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Ansary, T.M., Nakano, D., and Nishiyama, A. (2019). Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030629"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Manosroi, W., Danpanichkul, P., and Atthakomol, P. (2022). Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Aldosterone and Renin Levels in Diabetes Mellitus Type 2 Patients: A Systematic Review and Meta-Analysis. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-24280-9"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Adam, C.A., Anghel, R., Marcu, D.T.M., Mitu, O., Roca, M., and Mitu, F. (2022). Impact of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors on Arterial Stiffness and Vascular Aging\u2014What Do We Know So Far? (A Narrative Review). Life, 12.","DOI":"10.3390\/life12060803"},{"key":"ref_51","first-page":"169","article-title":"SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection","volume":"5","author":"Herat","year":"2020","journal-title":"J. Am. Coll. Cardiol. Basic Transl. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and Safety of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 2 Diabetes Mellitus: Systematic Review and Network Meta-Analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jdiacomp.2015.07.011","article-title":"Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials for 1 to 2 Years","volume":"29","author":"Liu","year":"2015","journal-title":"J. Diabetes Complicat."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"740","DOI":"10.7326\/M15-2650","article-title":"Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-Analysis","volume":"164","author":"Maruthur","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Mendez-Barbero, N., Oller, J., Sanz, A.B., Ramos, A.M., Ortiz, A., Ruiz-Ortega, M., and Rayego-Mateos, S. (2023). Mitochondrial Dysfunction in the Cardio-Renal Axis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098209"},{"key":"ref_57","first-page":"53","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors and Mitochondrial Functions: State of the Art","volume":"22","author":"Yaribeygi","year":"2023","journal-title":"EXCLI J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling\/Autophagy Hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.crphys.2022.05.003","article-title":"Empagliflozin Restores Cardiac Metabolic Flexibility in Diet-Induced Obese C57BL6\/J Mice","volume":"5","author":"Xie","year":"2022","journal-title":"Curr. Res. Physiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin Improves Muscle Insulin Sensitivity but Enhances Endogenous Glucose Production","volume":"124","author":"Merovci","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class Effects of SGLT2 Inhibitors in Mouse Cardiomyocytes and Hearts: Inhibition of Na+\/H+ Exchanger, Lowering of Cytosolic Na+ and Vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"104870","DOI":"10.1016\/j.phrs.2020.104870","article-title":"Empagliflozin protects heart from inflammation and energy depletion via AMPK activation","volume":"158","author":"Koyani","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/21623945.2020.1807850","article-title":"The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1\u03b1 signalling pathway","volume":"9","author":"Yang","year":"2020","journal-title":"Adipocyte"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Gao, Y.-M., Feng, S.-T., Wen, Y., Tang, T.-T., Wang, B., and Liu, B.-C. (2022). Cardiorenal protection of SGLT2 inhibitors-Perspectives from metabolic reprogramming. EBioMedicine, 83.","DOI":"10.1016\/j.ebiom.2022.104215"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Ren, C., Sun, K., Zhang, Y., Hu, Y., Hu, B., Zhao, J., He, Z., Ding, R., Wang, W., and Liang, C. (2021). Sodium-Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK-mTOR Signaling Pathway-Mediated Autophagy. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.664181"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"38690","DOI":"10.31083\/RCM38690","article-title":"Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists","volume":"26","author":"Bozkurt","year":"2025","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Rykova, E.Y., Klimontov, V.V., Shmakova, E., Korbut, A.I., Merkulova, T.I., and Kzhyshkowska, J. (2025). Anti-Inflammatory Effects of SGLT2 Inhibitors: Focus on Macrophages. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26041670"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Iannantuoni, F., M de Mara\u00f1on, A., Diaz-Morales, N., Falcon, R., Ba\u00f1uls, C., Abad-Jimenez, Z., Victor, V.M., Hernandez-Mijares, A., and Rovira-Llopis, S. (2019). The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes. J. Clin. Med., 8.","DOI":"10.3390\/jcm8111814"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Gohari, S., Ismail-Beigi, F., Mahjani, M., Ghobadi, S., Jafari, A., Ahangar, H., and Gohari, S. (2023). The effect of sodium-glucose co-transporter-2 (SGLT2) inhibitors on blood interleukin-6 concentration: A systematic review and meta-analysis of randomized controlled trials. BMC Endocr. Disord., 23.","DOI":"10.1186\/s12902-023-01512-1"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"865","DOI":"10.33594\/000000178","article-title":"Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor \u03b1-Stimulated Human Coronary Arterial Endothelial Cells","volume":"53","author":"Uthman","year":"2019","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Koizumi, T., Watanabe, M., Yokota, T., Tsuda, M., Handa, H., Koya, J., Nishino, K., Tatsuta, D., Natsui, H., and Kadosaka, T. (2023). Empagliflozin suppresses mitochondrial reactive oxygen species generation and mitigates the inducibility of atrial fibrillation in diabetic rats. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1005408"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7642","DOI":"10.1111\/jcmm.16601","article-title":"Dapagliflozin alleviates cardiac fibrosis through suppressing EndMT and fibroblast activation via AMPK\u03b1\/TGF-\u03b2\/Smad signalling in type 2 diabetic rats","volume":"25","author":"Tian","year":"2021","journal-title":"J. Cell. Mol. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"109825","DOI":"10.1016\/j.cellsig.2020.109825","article-title":"The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2\/ROS\/NLRP3\/Caspase-1-dependent IL-1\u03b2 and IL-18 secretion","volume":"77","author":"Sukhanov","year":"2021","journal-title":"Cell. Signal."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Yang, L., Zhang, X., and Wang, Q. (2022). Effects and mechanisms of SGLT2 inhibitors on the NLRP3 inflammasome, with a focus on atherosclerosis. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.992937"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.yjmcc.2022.03.005","article-title":"Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects","volume":"167","author":"Dyck","year":"2022","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41569-022-00824-4","article-title":"SGLT2 inhibitors: Role in protective reprogramming of cardiac nutrient transport and metabolism","volume":"20","author":"Packer","year":"2023","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"100207","DOI":"10.1016\/j.metop.2022.100207","article-title":"SGLT2 inhibition reduces myocardial oxygen consumption","volume":"15","author":"Lauritzen","year":"2022","journal-title":"Metab. Open"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1161\/CIRCRESAHA.116.309326","article-title":"Roles of Vascular Oxidative Stress and Nitric Oxide in the Pathogenesis of Atherosclerosis","volume":"120","author":"Xia","year":"2017","journal-title":"Circ. Res."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Meza, C.A., La Favor, J.D., Kim, D.-H., and Hickner, R.C. (2019). Endothelial Dysfunction: Is There a Hyperglycemia-Induced Imbalance of NOX and NOS?. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20153775"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"119731","DOI":"10.1016\/j.lfs.2021.119731","article-title":"Canagliflozin Ameliorates Aortic and Hepatic Dysfunction in Dietary-Induced Hypercholesterolemia in the Rabbit","volume":"280","author":"Ashry","year":"2021","journal-title":"Life Sci."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12933-017-0621-8","article-title":"Dapagliflozin Acutely Improves Endothelial Dysfunction, Reduces Aortic Stiffness and Renal Resistive Index in Type 2 Diabetic Patients: A Pilot Study","volume":"16","author":"Solini","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"20241012","DOI":"10.1515\/med-2024-1012","article-title":"Empagliflozin Improves Aortic Injury in Obese Mice by Regulating Fatty Acid Metabolism","volume":"19","author":"Yue","year":"2024","journal-title":"Open Med."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Karakasis, P., Theofilis, P., Patoulias, D., Vlachakis, P.K., Pamporis, K., Sagris, M., Ktenopoulos, N., Kassimis, G., Antoniadis, A.P., and Fragakis, N. (2025). Sodium-Glucose Cotransporter 2 Inhibitors in Aortic Stenosis: Toward a Comprehensive Cardiometabolic Approach. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26104494"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in Heart Failure with a Preserved Ejection Fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/ejhf.2249","article-title":"Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: Rationale and design of the DELIVER trial","volume":"23","author":"Solomon","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"SOLOIST-WHF Trial Investigators. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington, W.G., Staplin, N., Wanner, C., Green, J.B., Hauske, S.J., Emberson, J.R., Preiss, D., Judge, P., and Mayne, K.J. (2023). Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med., 388, 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/HYPERTENSIONAHA.116.07703","article-title":"Impact of Empagliflozin on Blood Pressure in Patients with Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication","volume":"68","author":"Mancia","year":"2016","journal-title":"Hypertension"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/ejhf.2286","article-title":"Cardiac, renal, and metabolic effects of sodium-glucose co-transporter 2 inhibitors: A position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter 2 inhibitors","volume":"23","author":"Herrington","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: Collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Baigent","year":"2022","journal-title":"Lancet"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1093\/ehjci\/jeae201","article-title":"Contemporary treatment options in heart failure with preserved ejection fraction","volume":"25","author":"Peikert","year":"2024","journal-title":"Eur. Heart J. Cardiovasc. Imaging"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.clinthera.2015.08.005","article-title":"Management of heart failure with preserved ejection fraction: A review","volume":"37","author":"Nanayakkara","year":"2015","journal-title":"Clin. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10557-023-07469-6","article-title":"Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes","volume":"39","author":"Escolar","year":"2025","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: A patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e14392","DOI":"10.1111\/eci.14392","article-title":"Sodium-glucose cotransporter 2 inhibitors and outcomes in transthyretin amyloid cardiomyopathy: Systematic review and meta-analysis","volume":"55","author":"Karakasis","year":"2025","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","article-title":"Impact of empagliflozin on decongestion in acute heart failure: The EMPULSE trial","volume":"44","author":"Biegus","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1111\/dom.14374","article-title":"Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis","volume":"23","author":"Giugliano","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","article-title":"Global Burden of Cardiovascular Diseases and Risks Collaborators. Global Burden of Cardiovascular Diseases and Risks, 1990\u20132022","volume":"82","author":"Mensah","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_109","first-page":"179","article-title":"Post-Myocardial Infarction Heart Failure","volume":"6","author":"Bahit","year":"2018","journal-title":"J. Am. Coll. Cardiol. Heart Fail."},{"key":"ref_110","first-page":"EVIDoa2300286","article-title":"Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM \u00c9vid."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after Acute Myocardial Infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40256-024-00662-4","article-title":"Empagliflozin Effects in Patients with ST-Elevation Myocardial Infarction Undergoing Primary PCI: The EMI-STEMI Randomized Clinical Trial","volume":"24","author":"Khani","year":"2024","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.2174\/0113816128304097240529053538","article-title":"Therapeutic Potential of Sodium-glucose Co-transporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists for Patients with Acute Coronary Syndrome: A Review of Clinical Evidence","volume":"30","author":"Karakasis","year":"2024","journal-title":"Curr. Pharm. Des."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","article-title":"Twenty-Four-Hour Blood Pressure-Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension: Results From the Randomized, Placebo-Controlled SACRA Study","volume":"139","author":"Kario","year":"2019","journal-title":"Circulation"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1097\/HJH.0000000000003280","article-title":"The Impact of Sodium-Glucose Cotransporter Inhibitors on Blood Pressure: A Meta-Analysis and Metaregression of 111 Randomized-Controlled Trials","volume":"40","author":"Teo","year":"2022","journal-title":"J. Hypertens."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Wei, R., Wang, W., Pan, Q., and Guo, L. (2022). Effects of SGLT-2 Inhibitors on Vascular Endothelial Function and Arterial Stiffness in Subjects with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.826604"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s13300-020-00885-z","article-title":"Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies","volume":"11","author":"Alshnbari","year":"2020","journal-title":"Diabetes Ther."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"48","DOI":"10.2337\/dsi23-0012","article-title":"Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies","volume":"37","author":"Genua","year":"2024","journal-title":"Diabetes Spectr."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients","volume":"42","author":"Honka","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-021-01237-2","article-title":"Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: The EMPACEF study","volume":"20","author":"Gaborit","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e019463","DOI":"10.1161\/JAHA.120.019463","article-title":"Effects of Sodium\/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials","volume":"10","author":"Teo","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_124","first-page":"gfaf051","article-title":"SGLT2 Inhibitors in CKD: Are They Really Effective in All Patients?","volume":"7","author":"Romagnani","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/dom.15696","article-title":"Key Results from Observational Studies and Real-World Evidence of Sodium-Glucose Cotransporter-2 Inhibitor Effectiveness and Safety in Reducing Cardio-Renal Risk","volume":"26","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"k119","DOI":"10.1136\/bmj.k119","article-title":"Cardiovascular Outcomes Associated with Canagliflozin versus Other Non-Gliflozin Antidiabetic Drugs: Population Based Cohort Study","volume":"360","author":"Patorno","year":"2018","journal-title":"BMJ"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.117.031227","article-title":"Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World","volume":"137","author":"Udell","year":"2018","journal-title":"Circulation"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1111\/dom.13424","article-title":"Comparative Effectiveness of Canagliflozin, SGLT2 Inhibitors and Non-SGLT2 Inhibitors on the Risk of Hospitalization for Heart Failure and Amputation in Patients With Type 2 Diabetes Mellitus: A Real-World Meta-Analysis of 4 Observational Databases (OBSERVE-4D","volume":"20","author":"Ryan","year":"2018","journal-title":"Diabetes, Obes. Metab."},{"key":"ref_129","first-page":"e134-40","article-title":"CNODES: The Canadian Network for Observational Drug Effect Studies","volume":"6","author":"Suissa","year":"2012","journal-title":"Open Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"l4772","DOI":"10.1136\/bmj.l4772","article-title":"Use of Sodium Glucose Cotransporter 2 Inhibitors and Risk of Major Cardiovascular Events and Heart Failure: Scandinavian Register Based Cohort Study","volume":"366","author":"Pasternak","year":"2019","journal-title":"BMJ"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"m1186","DOI":"10.1136\/bmj.m1186","article-title":"Use of Sodium-Glucose Co-Transporter 2 Inhibitors and Risk of Serious Renal Events: Scandinavian Cohort Study","volume":"369","author":"Pasternak","year":"2020","journal-title":"BMJ"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","article-title":"Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","article-title":"Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study","volume":"71","author":"Kosiborod","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-8587(19)30384-5","article-title":"Kidney Outcomes Associated with Use of SGLT2 Inhibitors in Real-World Clinical Practice (CVD-REAL 3): A Multinational Observational Cohort Study","volume":"8","author":"Heerspink","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1161\/CIRCULATIONAHA.118.039177","article-title":"Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care","volume":"139","author":"Patorno","year":"2019","journal-title":"Circulation"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"101418","DOI":"10.1016\/j.diabet.2022.101418","article-title":"Empagliflozin Cardiovascular and Renal Effectiveness and Safety Compared to Dipeptidyl Peptidase-4 Inhibitors Across 11 Countries in Europe and Asia: Results from the EMPagliflozin CompaRative EffectIveness and SafEty (EMPRISE) Study","volume":"49","author":"Karasik","year":"2023","journal-title":"Diabetes Metab."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s12933-023-01963-9","article-title":"Empagliflozin Is Associated with Lower Cardiovascular Risk Compared with Dipeptidyl Peptidase-4 Inhibitors in Adults With and Without Cardiovascular Disease: EMPagliflozin CompaRative EffectIveness and SafEty (EMPRISE) Study Results from Europe and Asia","volume":"22","author":"Vistisen","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/ehf2.15095","article-title":"Cardiac Remodelling in the Era of the Recommended Four Pillars Heart Failure Medical Therapy","volume":"12","author":"Colombo","year":"2025","journal-title":"ESC Heart Fail."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12968-020-00682-4","article-title":"SCMR Position Paper (2020) on Clinical Indications for Cardiovascular Magnetic Resonance","volume":"22","author":"Leiner","year":"2020","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s12933-025-02904-4","article-title":"Effect of SGLT2 inhibitors on cardiac structure and function assessed by cardiac magnetic resonance: A systematic review and meta-analysis","volume":"24","author":"Leo","year":"2025","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.1093\/eurheartj\/ehaa419","article-title":"A Randomized Controlled Trial of Dapagliflozin on Left Ventricular Hypertrophy in People with Type Two Diabetes: The DAPA-LVH Trial","volume":"41","author":"Brown","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Martuszewski, A., Paluszkiewicz, P., Por\u0119ba, R., and Ga\u0107, P. (2025). Clinical Significance of Extracellular Volume of Myocardium (ECV) Assessed by Computed Tomography: A Systematic Review and Meta-Analysis. J. Clin. Med., 14.","DOI":"10.37766\/inplasy2025.2.0109"},{"key":"ref_144","first-page":"1164","article-title":"Empagliflozin Reduces Myocardial Extracellular Volume in Patients with Type 2 Diabetes and Coronary Artery Disease","volume":"14","author":"Mason","year":"2021","journal-title":"J. Am. Coll. Cardiol. Cardiovasc. Imaging"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1186\/s40001-025-02834-7","article-title":"Impact of SGLT2 Inhibitors on Myocardial Fibrosis in Diabetic HFpEF: A Longitudinal Study","volume":"30","author":"Albulushi","year":"2025","journal-title":"Eur. J. Med Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e014655","DOI":"10.1136\/bmjopen-2016-014655","article-title":"Performance of Highly Sensitive Cardiac Troponin T Assay to Detect Ischaemia at PET-CT in Low-Risk Patients with Acute Coronary Syndrome: A Prospective Observational Study","volume":"7","author":"Morawiec","year":"2017","journal-title":"BMJ Open"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jacc.2021.11.027","article-title":"Stress Cardiac Biomarkers, Cardiovascular and Renal Outcomes, and Response to Canagliflozin","volume":"79","author":"Vaduganathan","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jacc.2017.06.016","article-title":"Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults with Type 2 Diabetes","volume":"70","author":"Januzzi","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/bcp.13903","article-title":"Effects of Dapagliflozin vs Vildagliptin on Cardiometabolic Parameters in Diabetic Patients with Coronary Artery Disease: A Randomised Study","volume":"85","author":"Phrommintikul","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1253\/circj.CJ-09-0834","article-title":"Plasma B-Type Natriuretic Peptide Level and Cardiovascular Events in Chronic Kidney Disease in a Community-Based Population","volume":"74","author":"Sakuma","year":"2010","journal-title":"Circ. J."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1373\/clinchem.2006.083170","article-title":"B-Type Natriuretic Peptide Concentrations Predict the Progression of Nondiabetic Chronic Kidney Disease: The Mild-to-Moderate Kidney Disease Study","volume":"53","author":"Spanaus","year":"2007","journal-title":"Clin. Chem."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.jacc.2021.07.046","article-title":"Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial","volume":"78","author":"Januzzi","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of Empagliflozin on Left Ventricular Volumes in Patients with Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1093\/eurheartj\/ehac494","article-title":"Empagliflozin in Acute Myocardial Infarction: The EMMY Trial","volume":"43","author":"Kolesnik","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.jacc.2020.09.004","article-title":"Effects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction","volume":"76","author":"Januzzi","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_157","doi-asserted-by":"crossref","unstructured":"Mart\u00edn, E., L\u00f3pez-Aguilera, J., Gonz\u00e1lez-Manzanares, R., Anguita, M., Guti\u00e9rrez, G., Luque, A., Paredes, N., Oneto, J., Perea, J., and Castillo, J.C. (2021). Impact of Canagliflozin in Patients with Type 2 Diabetes after Hospitalization for Acute Heart Failure: A Cohort Study. J. Clin. Med., 10.","DOI":"10.3390\/jcm10030505"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12933-021-01380-w","article-title":"Effects of Canagliflozin on NT-proBNP Stratified by Left Ventricular Diastolic Function in Patients with Type 2 Diabetes and Chronic Heart Failure: A Sub Analysis of the CANDLE Trial","volume":"20","author":"Kusunose","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ahj.2020.07.011","article-title":"Twelve Weeks of Treatment with Empagliflozin in Patients with Heart Failure and Reduced Ejection Fraction: A Double-Blinded, Randomized, and Placebo-Controlled Trial","volume":"228","author":"Jensen","year":"2020","journal-title":"Am. Heart J."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1002\/ehf2.12707","article-title":"Effects of Canagliflozin in Patients with Type 2 Diabetes and Chronic Heart Failure: A Randomized Trial (CANDLE)","volume":"7","author":"Tanaka","year":"2020","journal-title":"ESC Heart Fail."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"e015103","DOI":"10.1161\/JAHA.119.015103","article-title":"Effect of Luseogliflozin on Heart Failure With Preserved Ejection Fraction in Patients With Diabetes Mellitus","volume":"9","author":"Ejiri","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Peppa, M., Manta, A., Mavroeidi, I., Asimakopoulou, A., Syrigos, A., Nastos, C., Pikoulis, E., and Kollias, A. (2023). Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15112526"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jacc.2006.03.061","article-title":"Utility of Amino-Terminal Pro-Brain Natriuretic Peptide, Galectin-3, and Apelin for the Evaluation of Patients with Acute Heart Failure","volume":"48","author":"Januzzi","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1161\/CIRCHEARTFAILURE.112.000129","article-title":"Prognostic Value of Changes in Galectin-3 Levels Over Time in Patients with Heart Failure: Data from CORONA and COACH","volume":"6","author":"Gullestad","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"ref_165","doi-asserted-by":"crossref","unstructured":"Haller, P.M., Wiviott, S.D., Berg, D.D., Jarolim, P., Goodrich, E.L., Bhatt, D.L., Gause-Nilsson, I., Leiter, L.A., McGuire, D.K., and Wilding, J.P.H. (2025). Galectin-3 and kidney function in type 2 diabetes treated with dapagliflozin: Analysis from DECLARE-TIMI 58. ESC Heart Fail., submitted.","DOI":"10.1002\/ehf2.15415"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","article-title":"IL-33, an Interleukin-1-Like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines","volume":"23","author":"Schmitz","year":"2005","journal-title":"Immunity"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3B","DOI":"10.1016\/j.amjcard.2015.01.044","article-title":"The Biology of ST2: The International ST2 Consensus Panel","volume":"115","author":"Januzzi","year":"2015","journal-title":"Am. J. Cardiol."},{"key":"ref_168","first-page":"68","article-title":"Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure","volume":"4","author":"Tang","year":"2016","journal-title":"J. Am. Coll. Cardiol. Heart Fail."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1161\/CIRCHEARTFAILURE.113.001036","article-title":"Prognostic Value of Soluble ST2 in the Valsartan Heart Failure Trial","volume":"7","author":"Anand","year":"2014","journal-title":"Circ. Heart Fail."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 Inhibitor Dapagliflozin on Glomerular and Tubular Injury Markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes, Obes. Metab."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1080\/0886022X.2020.1801466","article-title":"Biomarker Evidence for Distal Tubular Damage but Cortical Sparing in Hospitalized Diabetic Patients with Acute Kidney Injury (AKI) While on SGLT2 Inhibitors","volume":"42","author":"Darawshi","year":"2020","journal-title":"Ren. Fail."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1001\/jama.289.19.2560","article-title":"The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report","volume":"289","author":"Chobanian","year":"2003","journal-title":"JAMA"},{"key":"ref_173","doi-asserted-by":"crossref","unstructured":"Cai, Y., Liu, X., and Xu, G. (2020). Combination Therapy with SGLT2 Inhibitors for Diabetic Kidney Disease. Biomed. Pharmacother., 127.","DOI":"10.1016\/j.biopha.2020.110192"},{"key":"ref_174","doi-asserted-by":"crossref","unstructured":"Zhao, L.-M., Zhang, M., Zhan, Z.-L., and Qiu, M. (2021). Does Combination Therapy with SGLT2 Inhibitors and Renin\u2013Angiotensin System Blockers Lead to Greater Reduction in Cardiorenal Events among Patients with Type 2 Diabetes?. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.679124"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients with Type 2 Diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Ferhatbegovi\u0107, L., Mr\u0161i\u0107, D., and Maci\u0107-D\u017eankovi\u0107, A. (2023). The Benefits of GLP1 Receptors in Cardiovascular Diseases. Front. Clin. Diabetes Healthc., 4.","DOI":"10.3389\/fcdhc.2023.1293926"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.cardfail.2025.01.022","article-title":"Efficacy of GLP-1 Receptor Agonists in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis","volume":"31","author":"Waqas","year":"2025","journal-title":"J. Card. Fail."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"SURMOUNT-1 Investigators. Tirzepatide for Obesity Treatment and Diabetes Prevention","volume":"392","author":"Halpern","year":"2025","journal-title":"N Engl J Med."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-Inflammatory Role of Glucagon-Like Peptide 1 Receptor Agonists and Its Clinical Implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_182","doi-asserted-by":"crossref","unstructured":"Mehdi, S.F., Pusapati, S., Anwar, M.S., Lohana, D., Kumar, P., Nandula, S.A., Nawaz, F.K., Tracey, K., Yang, H., and LeRoith, D. (2023). Glucagon-Like Peptide-1: A Multi-Faceted Anti-Inflammatory Agent. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1148209"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Li, Q., Lin, Y., Wang, S., Zhang, L., and Guo, L. (2017). GLP-1 Inhibits High-Glucose-Induced Oxidative Injury of Vascular Endothelial Cells. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-06712-z"},{"key":"ref_184","first-page":"1814","article-title":"GLP-1 Receptor Agonists Among Patients with Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors","volume":"12","author":"Patel","year":"2024","journal-title":"J. Am. Coll. Cardiol. Heart Fail."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1038\/s41591-024-03133-0","article-title":"Effects of Semaglutide with and without Concomitant SGLT2 Inhibitor Use in Participants with Type 2 Diabetes and Chronic Kidney Disease in the FLOW Trial","volume":"30","author":"Mann","year":"2024","journal-title":"Nat. Med."},{"key":"ref_186","first-page":"e078242","article-title":"Effect of Combination Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors on Incidence of Cardiovascular and Serious Renal Events: Population Based Cohort Study","volume":"385","author":"Treves","year":"2024","journal-title":"BMJ"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_188","first-page":"236","article-title":"Mineralocorticoid Receptor Antagonist Combined with SGLT2 Inhibitor versus SGLT2 Inhibitor Alone in Chronic Kidney Disease: A Meta-Analysis of Randomized Trials","volume":"56","author":"Ferreira","year":"2025","journal-title":"Am. J. Nephrol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1111\/dom.15232","article-title":"Estimated Lifetime Benefit of Novel Pharmacological Therapies in Patients with Type 2 Diabetes and Chronic Kidney Disease: A Joint Analysis of Randomized Controlled Clinical Trials","volume":"25","author":"Heerspink","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared with Conventional Care in Patients with Type 2 Diabetes and Albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"ref_191","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024). KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., 105, S117\u2013S314.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee, ElSayed, N.A., Aleppo, G., Bannuru, R.R., Bruemmer, D., Collins, B.S., Ekhlaspour, L., Gaglia, J.L., Hilliard, M.E., and Johnson, E.L. (2024). 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes\u20142024. Diabetes Care, 47, S158\u2013S178. Erratum in Diabetes Care 2024, 47, 1238.","DOI":"10.2337\/dc24-er07a"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"Metra","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"ESC Guidelines for the Management of Chronic Coronary Syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"ref_198","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ijcard.2022.06.059","article-title":"Safety outcomes of SGLT2i in the heart failure trials: A systematic review and Meta-analysis","volume":"366","author":"Younes","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12933-022-01476-x","article-title":"Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: A meta-analysis","volume":"21","author":"Kaze","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"493","DOI":"10.4103\/jfmpc.jfmpc_417_18","article-title":"Greater concern about hypoglycemia in Type 2 diabetics is the need of the hour-findings from a prospective, single-center, observational study","volume":"8","author":"Mohan","year":"2019","journal-title":"J. Family Med. Prim. Care."},{"key":"ref_202","doi-asserted-by":"crossref","unstructured":"Morace, C., Lorello, G., Bellone, F., Quartarone, C., Ruggeri, D., Giandalia, A., Mandraffino, G., Minutoli, L., Squadrito, G., and Russo, G.T. (2024). Ketoacidosis and SGLT2 Inhibitors: A Narrative Review. Metabolites, 14.","DOI":"10.3390\/metabo14050264"},{"key":"ref_203","doi-asserted-by":"crossref","unstructured":"Li, C.X., Liu, L.Y., Zhang, C.X., Geng, X.H., Gu, S.M., Wang, Y.Q., Liu, H., Xie, Q., and Liang, S. (2023). Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1238399"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Liu, H. (2024). Case literature analysis of Fournier\u2019s gangrene caused by sodium-glucose protein-2 inhibitors. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1301105"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"100261","DOI":"10.1016\/j.ahjo.2023.100261","article-title":"Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis","volume":"26","author":"Rivera","year":"2023","journal-title":"Am. Heart J. Plus Cardiol. Res. Pract."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.dsx.2020.02.012","article-title":"Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials","volume":"14","author":"Singh","year":"2020","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1681\/ASN.2022030373","article-title":"Sex Differences in the Recognition, Monitoring, and Management of CKD in Health Care: An Observational Cohort Study","volume":"33","author":"Swartling","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_209","doi-asserted-by":"crossref","unstructured":"Androutsakos, T., Nasiri-Ansari, N., Bakasis, A.-D., Kyrou, I., Efstathopoulos, E., Randeva, H.S., and Kassi, E. (2022). SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23063107"},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Huang, B., Yen, C.-L., Wu, C.-Y., Tsai, C.-Y., Chen, J.-J., Hsiao, C.-C., Chen, Y.-C., Hsieh, I.-C., and Yang, H.-Y. (2025). SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM. Sci. Rep., 15, Erratum in Sci. Rep. 2025, 15, 12440.","DOI":"10.1038\/s41598-024-81973-z"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejim.2024.09.020","article-title":"Comparative safety and efficacy analysis of GLP-1 receptor agonists and SGLT-2 inhibitors among frail individuals with type 2 diabetes in the era of continuous population ageing","volume":"131","author":"Karakasis","year":"2025","journal-title":"Eur. J. Intern. Med."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"afad254","DOI":"10.1093\/ageing\/afad254","article-title":"Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: A systematic review and meta-analysis","volume":"53","author":"Aldafas","year":"2024","journal-title":"Age Ageing"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2666-7568(23)00039-9","article-title":"SGLT2 inhibitors in older adults: Overcoming the age barrier","volume":"4","author":"Bellary","year":"2023","journal-title":"Lancet Healthy Longev."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/ndt\/gfaf022","article-title":"COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: Baseline clinical characteristics","volume":"40","author":"Agarwal","year":"2025","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s40265-024-02090-9","article-title":"GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy","volume":"84","author":"Scheen","year":"2024","journal-title":"Drugs"},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Karakasis, P., Sagris, M., Patoulias, D., Koufakis, T., Theofilis, P., Klisic, A., Fragakis, N., El Tanani, M., and Rizzo, M. (2024). Mitigating Increased Cardiovascular Risk in Patients with Obstructive Sleep Apnea Using GLP-1 Receptor Agonists and SGLT2 Inhibitors: Hype or Hope?. Biomedicines, 12.","DOI":"10.3390\/biomedicines12112503"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1903\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:17:26Z","timestamp":1761761846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/11\/1903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":216,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["medicina61111903"],"URL":"https:\/\/doi.org\/10.3390\/medicina61111903","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]}}}